ClinicalTrials.gg
TerminatedNCT00699283Updated Jul 11, 2018Results posted

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

A Phase 3 interventional study of Brivaracetam and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Terminated at 68 sites in 6 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
An interim analysis revealed the study was unlikely to attain a positive outcome for the efficacy analysis. No safety concerns were detected

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
21st of 34
62 · median 94
Started
2008
with 3 others
Phase 3
21 of 34
1 open now
Registered
11th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 21st largest by enrollment, is one of 4 that started in 2008, is one of 21 in phase 3, and was the 11th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy; Monotherapy
  • Partial Onset Seizures
  • Adults and Adolescents
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects from 16 to 75 years, both inclusive
  • Well-characterized focal epilepsy or epileptic syndrome
  • Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period
  • Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic Drugs (AEDs) with the second AED ≤ 50% of the minimum recommended maintenance dose

Exclusion criteria

Exclusion Criteria:

  • Seizure type IA non-motor as only seizure type
  • History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline
  • Other serious uncontrolled disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Brivaracetam (BRV) 1

    50 mg daily

    Drug: Brivaracetam

  • Experimental
    Brivaracetam (BRV) 2

    100 mg daily

    Drug: Brivaracetam

Interventions

  • 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)

    Also known as: ucb 34714

  • 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)

    Also known as: ucb 34714

06

What researchers measure

Primary outcomes

  1. The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase

    The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.

    Time frame: From Visit 4 (week 1) to the end of the Evaluation Period (week 17) (approximately 16 weeks)

07

Results

Posted Jan 18, 2017

Participant flow

This multi-Center study started to enroll subjects in August 2008 and concluded in March 2010.

Participant flow — Overall Study
MilestoneBrivaracetam (BRV) 50 mgBrivaracetam (BRV) 100 mg
Started4715
Completed147
Not completed338
Withdrew: Lack of efficacy155
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject10
Withdrew: Other reason51
Withdrew: Sae, non-fatal11
Withdrew: Ae, non-serious non-fatal81
Withdrew: Ae of unknown type10

Outcome measures

PrimaryThe Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase

The cumulative exit rate was estimated using Kaplan-Meier methods and was based on the duration between start of the Evaluation Period (EP) and the earliest date the first exit criterion was met for each subject. Subjects completing the EP without meeting an exit criterion were censored on Day 112. The primary comparison was BRV 50 mg/day vs a historical control. The upper limit of the 2-sided 95 % Confidence Interval for the estimate was compared to the historical lower bound estimate of 0.722.

Time frame:
From Visit 4 (week 1) to the end of the Evaluation Period (week 17) (approximately 16 weeks)
Reported as:
Number · percentage of subjects
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase
percentage of subjectsEfficacy Set (Brivaracetam 50 mg Treated Subjects)
The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase0.474 (0.310 to 0.638)

Adverse events

Collected over Adverse Events were collected from Week 0 over the 1-week BRV Add-On Period and the 15-week Evaluation Period until the end fo Follow-Up Period (Week 23) or Early Discontinuation Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam (BRV) 50 mg—3/47 (6.4%)31/47 (66%)
Brivaracetam (BRV) 100 mg—1/15 (6.7%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventBrivaracetam (BRV) 50 mgBrivaracetam (BRV) 100 mg
ConvulsionNervous system disorders0/471/15
Renal failure acuteRenal and urinary disorders0/471/15
Intentional overdoseInjury, poisoning and procedural complications1/470/15
EpilepsyNervous system disorders1/470/15
Status epilepticusNervous system disorders1/470/15
Suicide attemptPsychiatric disorders1/470/15
Most frequent other events
Showing 10 of 33
Most frequent other events
EventBrivaracetam (BRV) 50 mgBrivaracetam (BRV) 100 mg
DizzinessNervous system disorders7/472/15
FatigueGeneral disorders4/472/15
Decreased appetiteMetabolism and nutrition disorders1/472/15
ConvulsionNervous system disorders5/472/15
DepressionPsychiatric disorders3/472/15
IrritabilityGeneral disorders5/470/15
AstheniaGeneral disorders4/470/15
HeadacheNervous system disorders4/471/15
AnxietyPsychiatric disorders4/470/15
InsomniaPsychiatric disorders4/470/15

Baseline characteristics

Baseline Characteristics refer to the Intent-to-Treat Set (ITT), consisting of all randomized subjects with at least 1 intake of study medication.

Age, Categorical
Age, Categorical(Participants)Brivaracetam (BRV) 50 mgBrivaracetam (BRV) 100 mgTotal Title
<=18 years000
Between 18 and 65 Years451459
>=65 years213
Age, Continuous
Age, Continuous(years)Brivaracetam (BRV) 50 mgBrivaracetam (BRV) 100 mgTotal Title
Mean39.0 ± 13.844.3 ± 15.940.3 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam (BRV) 50 mgBrivaracetam (BRV) 100 mgTotal Title
Female271138
Male20424
08

Study locations

68 sites
  • Little Rock, Arkansas, United States
  • Garden Grove, California, United States
  • Loma Linda, California, United States
  • Newport Beach, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • Stanford, California, United States
  • Denver, Colorado, United States
  • Fort Collins, Colorado, United States
  • Danbury, Connecticut, United States
  • New Haven, Connecticut, United States
  • Waterbury, Connecticut, United States
  • Gainesville, Florida, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Honolulu, Hawaii, United States
  • Chicago, Illinois, United States
  • Danville, Indiana, United States
  • Elkhart, Indiana, United States
  • Waldorf, Maryland, United States
  • Grand Rapids, Michigan, United States
  • Columbia, Missouri, United States
  • Lebanon, New Hampshire, United States
  • Albuquerque, New Mexico, United States
  • Flushing, New York, United States
  • Schenectady, New York, United States
  • Charlotte, North Carolina, United States
  • Oberlin, Ohio, United States
  • Westerville, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Bethlehem, Pennsylvania, United States
  • Jenkintown, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Austin, Texas, United States
  • Bedford, Texas, United States
  • San Antonio, Texas, United States
  • Layton, Utah, United States
  • Ogden, Utah, United States
  • Burlington, Vermont, United States
  • Bluefield, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Marshfield, Wisconsin, United States
  • Bethune, France
  • Lille, France
  • Saint Brieuc, France
  • Toulouse, France
  • Berlin, Germany
  • Bernau, Germany
  • Bielefeld, Germany
  • Munchen, Germany
  • Munster, Germany
  • Ulm, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Kecskemet, Hungary
  • Szeged, Hungary
  • Bergamo, Italy
  • Firenze, Italy
  • Germaneto, Italy
  • Messina, Italy
  • Perugia, Italy
  • Pisa, Italy
  • Torino, Italy
  • Barcelona, Spain
  • Madrid, Spain
  • Murcia, Spain
  • Zaragoza, Spain
09

References and documents

Publications

  • Arnold S, Badalamenti V, Diaz A, Gasalla T, McShea C, Whitesides J, Fakhoury T. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies. Epilepsy Res. 2018 Mar;141:73-82. doi: 10.1016/j.eplepsyres.2018.02.005. Epub 2018 Feb 12. PubMed 29486396 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 6 years 10 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2008
First posted
Jun 17, 2008
Start
Aug 2008
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results delay requested
Apr 8, 2011
Results first posted
Jan 18, 2017
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00699283
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jun 17, 2008
Start date
Aug 2008
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jan 18, 2017
Last update
Jul 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion